Lu Xiangyi’s centrifuge helps propel original drug research and development toward new heights.

Release time:

2017-02-16


Overview:

After 3 to 5 years of operation, Chengdu Lead Discovery Pharmaceutical Co., Ltd. has essentially completed the establishment of a world-class R&D platform and R&D center for lead compounds. Currently, the ultra-large-capacity refrigerated centrifuge equipment purchased by the laboratory from Shanghai Luxiangyi has been operating smoothly and stably, and the centrifugation data obtained have consistently satisfied Chairman Li Jin. Li Jin stated that they have designated Shanghai Luxiangyi Centrifuge Equipment Co., Ltd. as their laboratory’s supplier, thereby helping Chengdu Lead Discovery Pharmaceutical Co., Ltd. advance to even higher levels in original drug research and development.

Introduction: He spent 27 years pursuing studies and conducting research in the UK, and for nearly 10 years served as an executive at a globally leading pharmaceutical company. In 2012, having passed the age of fifty, he gave up his high-paying overseas position and returned to China to start his own business, founding Chengdu Lead Discovery Pharmaceutical Co., Ltd. The company is dedicated to original drug research and development and has established China’s first—and the world’s fourth—“seed bank” for drug screening. After three to five years of operation, the company has essentially completed the construction of a world-class R&D platform and R&D center for lead compounds. Currently, the ultra-large-capacity refrigerated centrifuge equipment purchased from Shanghai Luxiangyi has been operating smoothly and stably in the laboratory, and the centrifugation data obtained have consistently satisfied Chairman Li Jin. Li Jin stated that they have specifically designated Shanghai Luxiangyi Centrifuge Equipment Co., Ltd. as their laboratory’s supplier, helping Chengdu Lead Discovery Pharmaceutical Co., Ltd. advance to even higher levels in original drug research and development.
 

    Tianfu Life Science Park, located at No. 88 Keyuan South Road in Chengdu High-Tech Zone, is a cluster of numerous buildings that houses a well-known domestic company specializing in original drug research and development—the Chengdu Lead Discovery Co., Ltd.


 

 

 

“Using computers to screen compounds” causes a sensation.

 
In 1963, Li Jin was born in Youyang, Chongqing. After graduating from university, he became one of the few overseas students at the time and went on to pursue a doctoral degree in macromolecular science at Aston University in the UK. His deep interest in scientific research then led him to join the postdoctoral program in theoretical biology at the prestigious University of Manchester in the UK, where he continued his advanced studies. After completing his doctorate, Li Jin stayed on at a small company founded by his postdoctoral supervisor. A year and a half later, dissatisfied with merely conducting conventional research on peptides and protein structures, he turned his attention to “small-molecule drug design based on protein structure”—a field that was still largely unexplored at the time. After submitting his research proposal, the company recognized its promising potential and entrusted him with an important role. At his request, the company hired five additional members, forming a basic research team.
 
Soon after, Li Jin’s research team became the first in the industry to leverage computer-assisted methods for large-scale compound library screening. In less than a week, they completed the screening of one million compounds, and most of the compounds identified through this screening were confirmed by experiments to possess biological activity. This groundbreaking research quickly stirred up a global sensation in the biopharmaceutical industry. The globally renowned pharmaceutical giant AstraZeneca, eager to recruit top talent, swiftly “poached” Li Jin.
 
Return to China and establish a “seed bank” for new drugs.
 
At AstraZeneca, Li Jin successively held the positions of Director of Computational Chemistry, Part-time Director of Structural Chemistry, and Global Director of Compound Science.
 
Since 2006, while serving as Global Director of Compound Science, Li Jin has been in charge of chemical outsourcing operations in multiple countries including China and Russia. His many years of experience working at international corporations have enabled him to gain a globally leading perspective and insight into industry trends.
  
In 2006, he was invited by the Chengdu Tianfu Life Science Park to attend a forum in Chengdu and deliver a speech. During his interactions with domestic pharmaceutical companies, Li Jin discovered that these companies lacked the capability to develop “original drugs,” and most were still at the stage of “contract manufacturing” and “generic drug production.”
 
“Many companies are imitating the same drug, and the profit margins are quite thin,” said Li Jin. From the perspective of a physician’s benevolent heart, simply relying on imitating drugs whose foreign patents have expired is insufficient to meet the treatment needs of the vast majority of patients.

 
In Li Jin’s view, for some serious diseases that currently lack effective treatments, only original drugs can offer patients truly effective therapeutic options. Among the more than 20,000 genes in the human genome lies the code governing human life, aging, illness, and death. To develop “targeted” drugs, we must identify the genes and their corresponding proteins that cause disease—and then find the “seeds” of drugs: lead compounds.
 

“I just wanted to come back home and do this,” said Li Jin. In the pharmaceutical industry, the difficulty of developing truly innovative new drugs is often described using the “three tens”: it takes ten years, costs 1 billion U.S. dollars, and ultimately the success rate is only 10%. In this sense, the final drug is like a towering tree, and the lead compound is merely a single seed from that tree. The “DNA-encoded small-molecule compound library” that Li Jin aims to build is precisely a vast repository of seeds for future drug screening—a foundation that will lay a strong groundwork for discovering new medicines.
 
In 2012, Li Jin, aged 50, gave up a high-paying job abroad and returned to China to found Chengdu Lead Discovery Co., Ltd.
 
Give small-molecule compounds an “ID card”
 
Shortly after its establishment, the company completed a high-standard laboratory spanning 1,500 square meters, which includes several biological and chemical laboratories as well as a chemical reagent storage facility.
 
To achieve technological leadership, Li Jin led his team in establishing China’s first “innovative platform for the synthesis of DNA-encoded small-molecule compound libraries and screening of lead compounds,” with the goal of identifying and optimizing drug “seeds”—lead compounds.
 
In the frozen laboratory located on the 8th floor, Li Jin donned gloves and opened a cold storage unit that held hundreds of millions of lead compounds. He took out a test tube about the size of a thumb, containing a compound of a certain formula that appeared transparent.
 
“There are 2.5 million small-molecule compounds in this test tube,” Li Jin said. This is his own patented invention, which solves the longstanding challenge of storing compounds.
 
According to traditional storage methods, one tube holds one single compound, and a single refrigerator can typically accommodate around 1,000 compound samples. Given Li Jin’s current collection of 1.3 billion compounds, it would take roughly 1.3 million such refrigerators to store them all—a number that is simply unfeasible given the current volume of compounds.
 
So, would putting 2.5 million compounds into a test tube the size of a thumb cause any confusion? “Not at all—each compound has a unique DNA-encoded identifier,” Li Jin said. This identifier is akin to a barcode, essentially serving as the compound’s “ID card.”
 
By the end of 2013, Li Jin had completed the synthesis of 300 million DNA-encoded compounds and screened 20 biological targets, and had also signed a commercial contract worth 10 million U.S. dollars. Today, the company has built an enormous library of DNA-encoded compounds, with the number of compounds now reaching 400 million—and by 2015, it had already reached 1 billion.
 
Li Jin said that the company currently provides services such as lead compound discovery and optimization primarily to large pharmaceutical companies both domestically and internationally. “These companies all need ‘seeds’ for innovative drug development in order to continuously develop new drugs and seek new growth opportunities.”
 
It is understood that the company has identified six distinct lead compounds in major disease areas such as diabetes, cardiovascular diseases, cancer, and respiratory disorders, and it will take only two years to ultimately develop these compounds into drugs.


Launch a collaborative project in Chongqing.
 
Since returning to China and starting his own business, he has been closely following the development of the biopharmaceutical industry in Chongqing. “Based on our understanding of various factors, Chongqing places great importance on the biopharmaceutical sector, and we’ve been actively seeking and exploring potential collaboration opportunities.” After operating for three to five years, the company has essentially completed the establishment of a world-class R&D platform and R&D center for lead compounds. Currently, the ultra-large-capacity refrigerated centrifuge equipment purchased from Shanghai Luxiangyi is performing consistently and stably in the lab, and the centrifugation data obtained have greatly satisfied Chairman Li Jin. Li Jin stated that they have designated Shanghai Luxiangyi Centrifuge Equipment Co., Ltd. as their laboratory’s supplier, helping Chengdu Lead Discovery Co., Ltd. advance to even higher levels in original drug research and development.